Patents by Inventor Allan Hamilton
Allan Hamilton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108846Abstract: A humidification system for delivering humidified gases to a user can include a heater base, humidification chamber having an inlet, outlet, and associated fluid conduit, and breathing circuit including a supply conduit, inspiratory conduit, and optional expiratory conduit. The humidification system can include various features to help make set-up less difficult and time-consuming. For example, the supply conduit, inspiratory conduit, and optional expiratory conduit can be coupled into a one-piece circuit to aid set-up. Various components can be color-coded and can have corresponding structures to indicate which components should be connected to one another during set-up. Such features can also help make the set-up process more intuitive for an operator, which can reduce the need for specialized training and reduce the number of potential errors.Type: ApplicationFiled: December 5, 2023Publication date: April 4, 2024Inventors: Jason Allan Klenner, Andrew Paul Maxwell Salmon, Mark Samuel Hamilton, James William Stanton, Michael John Andresen, Jonathan Andrew George Lambert
-
Publication number: 20220379380Abstract: Methods, systems, and apparatus, including medium-encoded computer program products, for computer aided design and manufacture of physical structures using hybrid additive and subtractive manufacturing include, in one aspect, a method including: obtaining data for 3D geometry of a part; simulating at least a portion of a manufacturing process that includes adding first material in a first stage and removing second material in a second, subsequent stage, where the second material includes a portion of the first material, removing the second material includes blending between the material added in the first and second stages, and thermal effects of adding and removing the material in the first and second stages is simulated; and adjusting an amount of the portion based on results of the simulating to prevent deviation of the part from the three dimensional geometry that results in not enough material being available for the blending.Type: ApplicationFiled: September 18, 2020Publication date: December 1, 2022Inventors: Lee Sanders, Robert Bowerman, Kelvin Samuel Allan Hamilton
-
Publication number: 20200247895Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: ApplicationFiled: March 31, 2020Publication date: August 6, 2020Applicant: The University of MelbourneInventors: John Allan Hamilton, Andrew David Cook
-
Publication number: 20180237531Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.Type: ApplicationFiled: April 17, 2018Publication date: August 23, 2018Inventors: Stefan STEIDL, John Allan HAMILTON, Andrew David COOK
-
Patent number: 10005840Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.Type: GrantFiled: December 16, 2015Date of Patent: June 26, 2018Assignees: MORPHOSYS AG, THE UNIVERSITY OF MELBOURNEInventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
-
Publication number: 20180066062Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: ApplicationFiled: November 13, 2017Publication date: March 8, 2018Applicant: The University of MelbourneInventors: John Allan Hamilton, Andrew David Cook
-
Patent number: 9834599Abstract: The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: GrantFiled: April 29, 2016Date of Patent: December 5, 2017Assignee: THE UNIVERSITY OF MELBOURNEInventors: John Allan Hamilton, Andrew David Cook
-
Publication number: 20160311896Abstract: The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: ApplicationFiled: April 29, 2016Publication date: October 27, 2016Inventors: John Allan Hamilton, Andrew David Cook
-
Publication number: 20160185867Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.Type: ApplicationFiled: December 16, 2015Publication date: June 30, 2016Inventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
-
Publication number: 20160185868Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: ApplicationFiled: December 18, 2015Publication date: June 30, 2016Inventors: John Allan Hamilton, Andrew David Cook
-
Patent number: 9352034Abstract: The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: GrantFiled: May 28, 2013Date of Patent: May 31, 2016Assignee: The University of MelbourneInventors: John Allan Hamilton, Andrew David Cook
-
Patent number: 9243066Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.Type: GrantFiled: July 17, 2012Date of Patent: January 26, 2016Assignees: University of Melbourne, Morpho Sys AGInventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
-
Patent number: 9243061Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: GrantFiled: December 21, 2009Date of Patent: January 26, 2016Assignee: University of MelbourneInventors: John Allan Hamilton, Andrew David Cook
-
Publication number: 20150368348Abstract: The present invention relates generally to a method for the treatment and prophylaxis of inflammatory conditions. The present invention is predicated in part on the identification of cells of the monocyte/macrophage lineage being critical for inflammation and, in particular, chronic inflammation. In accordance with the present invention, it is proposed that the reduction in levels of monocyte/macrophage-type cells and/or a reduction in the production of inflammatory and pro-inflammatory mediators by these cells, especially locally, is effective in reducing inflammatory conditions. The present invention further provides animal models useful for screening for reducing levels of monocyte/macrophage-type cells and/or reducing the production of inflammatory and pro-inflammatory mediators of these cells.Type: ApplicationFiled: May 19, 2015Publication date: December 24, 2015Inventors: John Allan Hamilton, Gary Peter Anderson, Ian Keith Campbell
-
Publication number: 20150017180Abstract: A method for the treatment of a chronic inflammatory condition in a patient which comprises administration to the patient of an agent which blocks or inhibits IL-3 signalling events in the patient.Type: ApplicationFiled: May 12, 2014Publication date: January 15, 2015Applicant: CSL LimitedInventors: Gino Luigi Vairo, John Allan Hamilton, Andrew David Cook
-
Publication number: 20140205608Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.Type: ApplicationFiled: July 17, 2012Publication date: July 24, 2014Applicants: MorphoSys AG, The University of MelbourneInventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
-
Publication number: 20130243791Abstract: The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: ApplicationFiled: May 28, 2013Publication date: September 19, 2013Applicant: The University of MelbourneInventors: John Allan Hamilton, Andrew David Cook
-
Patent number: 8475796Abstract: The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: GrantFiled: December 21, 2009Date of Patent: July 2, 2013Assignee: University of MelbourneInventors: John Allan Hamilton, Andrew David Cook
-
Publication number: 20120003234Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: ApplicationFiled: December 21, 2009Publication date: January 5, 2012Applicant: THE UNIVERSITY OF MELBOURNEInventors: John Allan Hamilton, Andrew David Cook
-
Publication number: 20110287027Abstract: The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.Type: ApplicationFiled: December 21, 2009Publication date: November 24, 2011Applicant: THE UNIVERSITY OF MELBOURNEInventors: John Allan Hamilton, Andrew David Cook